MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents

Show full item record



Permalink

http://hdl.handle.net/10138/324507

Citation

Bolomsky , A , Vogler , M , Kose , M C , Heckman , C A , Ehx , G , Ludwig , H & Caers , J 2020 , ' MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents ' , Journal of Hematology & Oncology , vol. 13 , no. 1 , 173 . https://doi.org/10.1186/s13045-020-01007-9

Title: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
Author: Bolomsky, Arnold; Vogler, Meike; Kose, Murat Cem; Heckman, Caroline A.; Ehx, Gregory; Ludwig, Heinz; Caers, Jo
Contributor: University of Helsinki, Research Programs Unit
Date: 2020-12-11
Language: eng
Number of pages: 19
Belongs to series: Journal of Hematology & Oncology
ISSN: 1756-8722
URI: http://hdl.handle.net/10138/324507
Abstract: Cell death escape is one of the most prominent features of tumor cells and closely linked to the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic family member myeloid cell leukemia-1 (MCL-1) acts as a master regulator of apoptosis in various human malignancies. Irrespective of its unfavorable structure profile, independent research efforts recently led to the generation of highly potent MCL-1 inhibitors that are currently evaluated in clinical trials. This offers new perspectives to target a so far undruggable cancer cell dependency. However, a detailed understanding about the tumor and tissue type specific implications of MCL-1 are a prerequisite for the optimal (i.e., precision medicine guided) use of this novel drug class. In this review, we summarize the major functions of MCL-1 with a special focus on cancer, provide insights into its different roles in solid vs. hematological tumors and give an update about the (pre)clinical development program of state-of-the-art MCL-1 targeting compounds. We aim to raise the awareness about the heterogeneous role of MCL-1 as drug target between, but also within tumor entities and to highlight the importance of rationale treatment decisions on a case by case basis.
Subject: Myeloid cell leukemia 1
MCL-1
BCL-2
Dependency
Inhibitor
Apoptosis
Cancer
Leukemia
Myeloma
Lymphoma
Melanoma
CHRONIC LYMPHOCYTIC-LEUKEMIA
MYELOID CELL LEUKEMIA-1
BCL-2 FAMILY PROTEINS
ANTI-APOPTOTIC MCL-1
MULTIPLE-MYELOMA
TARGETED THERAPY
MULTIKINASE INHIBITOR
SURVIVAL FACTOR
POOR-PROGNOSIS
PIVOTAL ROLE
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s13045_020_01007_9.pdf 1.589Mb PDF View/Open
Correction_to_MCL_1_inhibitors_fast_l...pdf 141.3Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record